Jade Biosciences (JBIO) Cash from Investing Activities (2021 - 2026)

Jade Biosciences (JBIO) has 6 years of Cash from Investing Activities data on file, last reported at -$8.5 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 165.91% year-over-year to -$8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$268.3 million (down 1132.86% YoY) and the FY2025 annual result came in at -$247.0 million, down 540.85% from the prior year.
• Cash from Investing Activities rose to -$8.5 million in Q1 2026, from -$98.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $15.4 million in Q1 2023 to a low of -$148.7 million in Q3 2025.
• A 5-year average of -$14.3 million and a median of $4.6 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 8394.64% in 2022, down 50897.5% in 2022.
• Tracing JBIO's Cash from Investing Activities over 5 years: stood at $14.5 million in 2022, then slumped by 61.01% to $5.6 million in 2023, then surged by 132.45% to $13.1 million in 2024, then plunged by 847.67% to -$98.2 million in 2025, then jumped by 91.37% to -$8.5 million in 2026.
• The last three Cash from Investing Activities figures came in at -$8.5 million (Q1 2026), -$98.2 million (Q4 2025), and -$148.7 million (Q3 2025), per Business Quant data.